INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 426m ago
HOUSE PTR26m ago
SEC 13F26m ago
ROBINHOOD CHAIN26m ago
Public company

STOKStoke Therapeutics, Inc.

CIK 0001623526

EDGAR filingsOpen in network
Disclosed transactions59
Buys / sells0 / 47
Max Insider Score40
Connections9with evidence

STOK · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$5,398
200 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Cumbo AlexanderDirector · Sep 25, 2026
  • ← Lobbied forevidence
    FEROX STRATEGIESLDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Kahn ClareDirector · Apr 7, 2026
9
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$185K
6,995 sh
Nov 2, 2026
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC FORM 4

Evidence

0
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$17K
627 sh
Oct 2, 2026Oct 2, 2026
traded Oct 2, 2026
+0dSEC FORM 4

Evidence

9
CA
Cumbo AlexanderDirector
STOKStoke Therapeutics, Inc.
Grant or award
A—
39.7K sh
Sep 23, 2026Sep 25, 2026
traded Sep 23, 2026
+2dSEC FORM 4

Evidence

2
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$44K
1,457 sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

9
KC
Kahn ClareDirector
STOKStoke Therapeutics, Inc.
Grant or award
A—
30.8K sh
Apr 3, 2026Apr 7, 2026
traded Apr 3, 2026
+4dSEC FORM 4

Evidence

13
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$21K
601 sh
Mar 20, 2026Mar 24, 2026
traded Mar 20, 2026
+4dSEC FORM 4

Evidence

27
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$292K
8,692 sh
Mar 20, 2026Mar 24, 2026
traded Mar 20, 2026
+4dSEC FORM 4

Evidence

20
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$191K
6,100 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

13
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$3,384
103 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

0
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2,989
1,365 sh
Mar 19, 2026Mar 19, 2026
traded Mar 19, 2026
+0dSEC FORM 4

Evidence

13
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$44K
1,461 sh
Mar 19, 2026Mar 19, 2026
traded Mar 19, 2026
+0dSEC FORM 4

Evidence

0
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,365 sh
Mar 19, 2026Mar 19, 2026
traded Mar 19, 2026
+0dSEC FORM 4

Evidence

32
LT
Leggett ThomasChief Financial Officer
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$1,215
37 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

39
LT
Leggett ThomasChief Financial Officer
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$68K
2,173 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

40
HJ
Hoitt JasonChief Patient Officer
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$34K
1,033 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

40
HJ
Hoitt JasonChief Patient Officer
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$25K
748 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

39
HJ
Hoitt JasonChief Patient Officer
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$55K
1,762 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

32
HJ
Hoitt JasonChief Patient Officer
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$4,419
139 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

32
HJ
Hoitt JasonChief Patient Officer
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$986
30 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

40
LT
Leggett ThomasChief Financial Officer
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$31K
922 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

40
LT
Leggett ThomasChief Financial Officer
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$42K
1,274 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

13
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$15K
483 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

36
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$81K
2,476 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

36
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$60K
1,791 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

36
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$132K
4,222 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

29
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$11K
334 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

29
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$2,365
72 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

20
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$117K
3,577 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

20
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$86K
2,587 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

32
LT
Leggett ThomasChief Financial Officer
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$5,468
172 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

2
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Grant or award
A—
35.0K sh
Feb 17, 2026Feb 19, 2026
traded Feb 17, 2026
+2dSEC FORM 4

Evidence

2
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Grant or award
A—
53.0K sh
Feb 17, 2026Feb 19, 2026
traded Feb 17, 2026
+2dSEC FORM 4

Evidence

12
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$41K
1,300 sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

15
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$87K
2,678 sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

0
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,000 sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

7
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
10.0K sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

15
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$42K
1,373 sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

11
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$10K
323 sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

15
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$52K
1,673 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

15
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$62K
1,989 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

0
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
10.0K sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

3
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,000 sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

11
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$6,075
194 sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

8
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$31K
1,004 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

19
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$169K
5,437 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

11
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$25K
824 sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

15
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$74K
2,344 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

9
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Option exercise
M—
12.4K sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

31
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$43K
1,394 sh
Dec 3, 2025Dec 3, 2025
traded Dec 3, 2025
+0dSEC FORM 4

Evidence

35
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$42K
1,416 sh
Dec 2, 2025Dec 3, 2025
traded Dec 2, 2025
+1dSEC FORM 4

Evidence

27
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$27K
898 sh
Dec 3, 2025Dec 3, 2025
traded Dec 3, 2025
+0dSEC FORM 4

Evidence

31
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Open-market sale
SELL$26K
868 sh
Dec 2, 2025Dec 3, 2025
traded Dec 2, 2025
+1dSEC FORM 4

Evidence

21
AJ
Allan JonathanGENERAL COUNSEL & CORP SEC
STOKStoke Therapeutics, Inc.
Option exercise
M—
12.4K sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

28
KR
Krainer Adrian R.Director
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.20M
40.5K sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

16
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$95K
3,776 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

9
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$17K
600 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

5
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$2,935
100 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

9
TB
Ticho BarryCHIEF MEDICAL OFFICER
STOKStoke Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$38K
1,455 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Hoitt JasonChief Patient Officer · Mar 19, 2026
  • ← Insider ofevidence
    Leggett ThomasChief Financial Officer · Mar 19, 2026
  • ← Insider ofevidence
    Allan JonathanGENERAL COUNSEL & CORP SEC · Dec 3, 2025
  • ← Insider ofevidence
    Krainer Adrian R.Director · Nov 26, 2025
  • ← Insider ofevidence
    Ticho BarryCHIEF MEDICAL OFFICER · Nov 5, 2025

    • Lobbying

    $80K reported · de-duplicated
    2026 Q2 $40K via firms2026 Q1 $40K via firms
    • FEROX STRATEGIES$40K2026 Q1 · posted Aug 26, 2026 · Health issues
    • FEROX STRATEGIES$40K2026 Q2 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.